Detailed Narrative
Q4 and FY26 Performance Overview
Blue Jet Healthcare reported Q4 FY26 revenue of INR235 crores, marking a 22% sequential increase but a 31% year-over-year decline. For the full fiscal year 2026, revenue from operations stood at INR947 crores, an 8% decrease compared to FY25. Gross margin for Q4 FY26 was 56%, up from 52% in Q3, while the full-year gross margin was 54% (down from 55% in FY25). FY26 EBITDA was 31% (vs 37% in FY25), and PAT was 26% (vs 30% in FY25), primarily impacted by lower volumes in the PI/API segment.
Segmental Performance: Contrast Media Leads Growth
The Contrast Media segment demonstrated strong momentum, with Q4 FY26 revenue surging 91% YoY to INR193 crores and 55% QoQ. For FY26, this segment grew 23% YoY to INR495 crores. In contrast, the PI/API segment faced significant headwinds due to customer destocking, resulting in Q4 FY26 revenue of only INR2.4 crores, a sharp drop from INR196 crores in Q4 FY25. The full-year PI/API revenue declined 35% to INR298 crores. The Artificial Sweetener segment saw Q4 revenue of INR37 crores (up 43% QoQ) but a 24% YoY decline, with FY26 revenue down 2% to INR131 crores due to pricing pressure.
Strategic Investments and Capacity Expansion
A key highlight was the commencement of the Vizag greenfield expansion project, which is envisaged to cost approximately INR1,000 crores over three years. This facility will develop dedicated manufacturing blocks for contrast media intermediates, high-intensity sweeteners, and pharma intermediates, with capacity expected to come online in 24-30 months. Additionally, the Mahad Unit 3 site is progressing well on backward integration for key raw materials and is expected to start production in H2 FY27. The company also plans to invest INR40 crores in an R&D center in Hyderabad, focusing on new chemistry platforms like peptides and biocatalysts.
Future Growth Drivers and Pipeline
Management expressed confidence in FY27, anticipating improved visibility and double-digit growth, supported by new product launches and healthy customer engagement in the contrast media segment. The PI/API segment is expected to normalize📎 as destocking is complete, with new orders in hand. The company is tracking approximately 20 active RFPs in the PI/CDMO segment, with two opportunities expected to move to commercialization in the current year. Two high-conviction commercial-stage opportunities are also being evaluated for strategic lateral entries, with dedicated capacity factored into Vizag planning.
Operational Efficiency and Sustainability
Blue Jet Healthcare continues its focus on sustainability, with close to 70% of its energy consumption supported by renewables. The company was awarded the CII National Award for Excellence in Energy Management. While rupee depreciation in FY26 helped negate raw material price increases, the impact of rising crude oil prices and logistics costs post March '26 will need careful evaluation in FY27, potentially affecting cost structures and margins.
Capital Allocation and Financial Health
The company maintains a strong financial position, ending FY26 as a debt-free entity. Liquid financial assets increased to INR400 crores at FY26 end, up from INR306 crores in FY25. Cash flow from operating activities stood at INR334 crores. For FY27, the company plans a capex of approximately INR400 crores, allocated towards the Vizag greenfield project, completion of Mahad, and additions in Ambernath, aligning investments with customer engagement and future product opportunities.